MetaVia's DA-1726 Shows 9.1% Weight Loss in Phase 1 Trial; Vanoglipel Combos Boost Metabolic Effects
Event summary
- DA-1726 achieved 9.1% mean body weight reduction at 48 mg dose in Phase 1 trial without evidence of plateau
- Vanoglipel combined with resmetirom showed 23.6% weight reduction in MASH mouse model
- Vanoglipel + metformin combo reduced body weight by 16.3% in T2D mouse model
- Phase 1 Part 3 titration study results for DA-1726 expected Q4 2026
The big picture
MetaVia's data positions DA-1726 as a potential best-in-class obesity treatment, while vanoglipel's combination potential could expand its addressable market in MASH and type 2 diabetes. The results come as competition in the obesity and metabolic disease space intensifies, with established players like Novo Nordisk and Eli Lilly dominating the GLP-1 agonist market. MetaVia's ability to differentiate its pipeline through combination therapies will be key to gaining market share.
What we're watching
- Clinical Validation
- Whether DA-1726 can sustain progressive weight loss in higher-dose evaluations
- Combination Strategy
- How vanoglipel's synergistic effects will position it in MASH and T2D markets
- Regulatory Pathway
- The pace at which MetaVia advances DA-1726 and vanoglipel through Phase 1 Part 3 studies
Related topics